Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call
Rhea-AI Summary
Zevra Therapeutics (NasdaqGS: ZVRA) will release its Q2 2026 corporate and financial results on Wednesday, August 5, 2026, via news release after market close, followed by a conference call and audio webcast at 4:30 p.m. ET.
According to Zevra, the live webcast and a 90-day replay will be available on the “Events & Presentations” page in the Investor Relations section of investors.zevra.com. Investors can also join via telephone using U.S. dial-in (800) 274-8461, international dial-in +1 (203) 518-9814, and Conference ID ZVRAQ226.
Positive
- None.
Negative
- None.
News Market Reaction – ZVRA
In the Jul 22 session, ZVRA declined 2.49%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Q1 results | Positive | -2.2% | Revenue growth, asset sale, debt prepayment, and pipeline progress accompanied negative share reaction. |
| Apr 22 | Q1 call notice | Neutral | +1.9% | Scheduled first-quarter results release and conference call details preceded a positive reaction. |
| Mar 09 | FY2025 results | Positive | +21.3% | Revenue, net income, cash, and pipeline updates preceded a 21.27% positive reaction. |
| Mar 02 | Q4 call notice | Neutral | +1.8% | Scheduled fourth-quarter and full-year results call preceded a positive reaction. |
| Nov 05 | Q3 results | Positive | -9.7% | Revenue growth, reduced loss, cash, and pipeline progress preceded a negative reaction. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-tagged announcements produced mixed reactions, with an average move of 2.6% across five events.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced it will report corporate and financial results for the second quarter on Wednesday, August 5, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day.
A link to the audio webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com.
To join via telephone, please use the following dial-in information:
- (800) 274-8461 (United States)
- +1 (203) 518-9814 (International)
- Conference ID: ZVRAQ226
A replay of the webcast will be available for 90 days beginning at approximately 5:30 p.m. ET. The replay will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 9, 2026, and Zevra's other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Investor Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Media Contact
Julie Downs
+1 (508) 246-3230
jdowns@zevra.com
